Pipeline

We are developing a differentiated portfolio of RNA-based immunotherapies to transform outcomes for patients with cancer.
Therapy
Indications
Development Stage
Research
IND-enabling
Phase 1
Phase 2
Phase 3
Commercial Rights
ONCR-021
NSCLC
HCC
ccRCC
Melanoma
ATC
ONCR-788
SCLC
Prostate and other neuroendocrine tumors
ONCR-719
Glioblastoma multiforme
Other CNS tumors
ccRCC = clear cell renal cell carcinoma; CNS = central nervous system; GBM = glioblastoma multiforme; HCC = hepatocellular carcinoma; IND = investigational new drug; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer; vRNA = viral RNA; ATC = anaplastic thyroid cancer If you are interested in partnering with Oncorus, please contact us.